| 1. |
?余翠琴.凱時的制劑特點.中國醫院藥學雜志, 2002, 22(11):691-692.
|
| 2. |
勞海燕, 王啟儀, 楊敏, 等.廣東省人民醫院超說明書用藥臨床管理方法與流程研究.中國循證醫學雜志, 2014, 14(9):1025-1029.
|
| 3. |
林璐, 曾英彤, 劉曉琦, 等.廣東省人民醫院2012年住院患者前列地爾注射劑超說明書用藥情況調查.中國循證醫學雜志, 2014, 14(9):1038-1043.
|
| 4. |
Dong M, Ma Z, Chai S, et al. Effect of Prostaglandin E 1 on Pulmonary Arterial Hypertension Following Corrective Surgery for Congenital Heart Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17(3):303-307.
|
| 5. |
Song JS, Seo JJ, Moon HN, et al. Prophylactic Low-dose Heparin or Prostaglandin E1 may Prevent Severe Veno-occlusive Disease of the Liver after Allogeneic Hematopoietic Stem Cell Transplantation in Korean Children. J Korean Med Sci, 2006, 21(5):897-903.
|
| 6. |
高國棟, 龍村, 謝穎, 等.前列地爾對體外循環心瓣膜替換術患者術中的心肌保護作用.中華臨床醫學雜志, 2008, 9(6):5-7.
|
| 7. |
武瓊, 趙明, 韓秀敏, 等.前列地爾治療重癥心力衰竭并腎功能不全患者安全性及有效性觀察.中國臨床實用醫學, 2015, 6(3):21-24.
|
| 8. |
Hou Z, Sun Z, Su C, et al. Effect of lipo-prostaglandin E1 on cystatin C, b2-microglobulin, and estimated glomerular filtration rate in patients with decompensated heart failure and renal dysfunction:a single-center, nonrandomized controlled study. Heart Vessels, 2013, 28(5):589-595.
|
| 9. |
Ahn J, Kim T, Kim Y, et al. Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes. Diabetic Medicine, 2006, 23(12):1339-1343.
|
| 10. |
方朝暉, 趙進東, 丁雷, 等.前列地爾對糖尿病性周圍神經病變患者神經傳導速度作用的系統評價.中華中醫藥學刊, 2015, 33(9): 2058-2061.
|
| 11. |
Cao M, Ke K, Sun H, et al. Effects of prostaglandin E1 on perihematomal tissue after hypertensive intracerebral hemorrhage. Acta Neurol Taiwan, 2011, 20(3):172-181.
|
| 12. |
孫艷, 李曉濤.前列地爾治療先天性心臟病并發肺動脈高壓50例療效觀察.陜西醫學雜志, 2013, 42(1):97-98.
|
| 13. |
黃麗彬, 嚴瑾, 王玉芳, 等.前列地爾治療肝硬化失代償期合并肝腎綜合征的療效觀察.華西藥學雜志, 2005, 20(2):178-179.
|
| 14. |
Ikegami T, Matsuzaki Y, Yoshiga S, et al. Randomized control trial of lipo-prostaglandin E, in patients with acute liver injury induced by Lipiodol-targeted chemotherapy. Gastroenterology, 1995, 108(4): 582-589.
|
| 15. |
Tian J, Chan JH, Li Q, et al. Lipid peroxidation in IgA nephropathy and effect of lipo-prostaglandin E1. J Nephrol, 2005, 18(3):243-248.
|
| 16. |
韓寬懷, 張中偉, 凌光文.不同劑量前列地爾對大范圍肝切除術后患者肝腎功能影響的觀察.人民軍醫, 2015, 58(4):396-397.
|
| 17. |
金海加, 任芳.不同劑量前列地爾聯合依帕司他治療糖尿病痛性神經病變療效觀察.中國新藥雜志, 2014, 23(12):1427-1437.
|
| 18. |
林建輝, 張元芬, 陳明勝.不同劑量前列地爾應用于肝衰竭患者的臨床療效觀察.中國醫藥指南, 2012, 10(16):171-173.
|
| 19. |
廣東省藥學會.藥品未注冊用法專家共識.今日藥學, 2010, 20(4): 2.
|
| 20. |
江俊, 宋民憲, 唐冬蕾.超藥品說明書用藥的法律責任研究.中藥與臨床, 2014, 5(2):87-89.
|
| 21. |
張曉寧.不同劑量前列地爾注射液治療早期糖尿病腎病的臨床觀察.中日友好醫院學報, 2012, 26(5):284-286.
|
| 22. |
高琲, 劉芳, 張俊.靜脈給予前列地爾致靜脈炎:246份報告分析.藥物不良反應雜志, 2011, 13(6):354-358.
|
| 23. |
紀立偉, 邢麗秋, 周冰, 等.前列地爾注射液的不良反應/不良事件評價.中國新藥雜志, 2014, 23(5):610-614.
|